Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
834 Retinoid X receptor agonists enhances type I systemic and intratumoral immunity, but enhanced tumor prevention, with the HER2-IGFBP2-IGF1R plasmid vaccine in two mouse mammary tumor models
Compose a Response to This Article
Other responses
No responses have been published for this article.
